Un-Audited Financial Results (UFR) for the Second quarter and Half Year ended September 30, 2025, along with the Statutory Auditors' Limited Review Report pursuant to Regulation 33 of the ....
Awaiting price reaction for this filing.
The board of Kashyap Tele-Medicines Limited approved the unaudited financial results for Q2 FY26 and the half-year ended September 30, 2025, on November 12, 2025. Revenue from operations dropped sharply to ₹5.50 lakhs in Q2 FY26 from ₹19.20 lakhs in Q2 FY25 — a decline of roughly 71%. The company slipped into a net loss of ₹5.68 lakhs in Q2 FY26, compared to a small profit of ₹0.44 lakhs in the same quarter last year. For the half year, revenue stood at around ₹16.90 lakhs versus ₹19.20 lakhs earlier, and the company posted a loss of ₹8.69 lakhs against a profit of ₹0.78 lakhs in H1 FY25. Earnings per share turned negative at (₹0.018) for H1 FY26. The statutory auditor, Shah Valera & Associates LLP, issued an unqualified limited review report with no qualifications or emphasis-of-matter flags. Other equity remains deeply negative at (₹421.24 lakhs), reflecting accumulated losses.
Sharp revenue decline, swing to losses and persistently negative shareholder equity are negative signals for the stock, even though operating cash flow turned positive (₹61 lakhs) and the auditor gave a clean review. Shareholders should watch closely for any turnaround in the core 'Software Sales' business.